Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET

Company Participants

Ryan Crowe - Senior Vice President, Investor Relations
Leonard Schleifer - Board Co-Chair, Co-Founder, President & Chief Executive Officer
George Yancopoulos - Board Co-Chair, Co-Founder, President & Chief Scientific Officer
Marion McCourt - Executive Vice President, Commercial
Chris Fenimore - Senior Vice President & Chief Financial Officer

Conference Call Participants

Colin Bristow - UBS
Evan Seigerman - BMO Capital Markets
Christopher Raymond - Piper Sandler
Salveen Richter - Goldman Sachs
Tyler Van Buren - TD Cowen
Terence Flynn - Morgan Stanley
William Pickering - Bernstein
Carter Gould - Barclays
Brian Abrahams - RBC Capital Markets
Mohit Bansal - Wells Fargo

Operator

Welcome to the Regeneron Pharmaceuticals First Quarter 2024 Earnings Conference Call. My name is Josh, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded.

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe

Thanks, Josh. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our first quarter 2024 earnings conference call.

An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after the call ends.

Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore, Senior Vice President and Chief Financial Officer.

After our prepared remarks, the remaining time will be available for your questions. We anticipate today's call will last approximately 60 minutes.

I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement issues, intellectual property, pending litigation and other proceedings and competition.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2024, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.